Bayer Pares Dr. Scholl's In Latest Step Toward Core Consumer Portfolio
Bayer follows through on plans to divest Dr. Scholl’s after selling Coppertone business in May to focus on consumer lines such as Aleve oral analgesics, Claritin allergy treatments and Bayer Aspirin. Private equity firm Yellow Wood Partners creating stand-alone company to operate Dr. Scholl's.
You may also be interested in...
Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.